PARP1 and cancer: For SKOV3 cells, the combination of olaparib or fluazolepali with ATO at 25, 50, 75, 100, or 125% of IC50s showed a significant collaboration on the cancer cell viabilities, given that the addition of ATO greatly reduced cell viabilities than the PARP inhibitors alone and that the according CI values were below 1.